Founded in 2003, Ypsomed Holding (YPSN) has established itself as the world’s leading producer and provider of injection and infusion systems and diabetes care products for pharmaceutical and biotech companies. Headquartered in Burgdorf, Switzerland, the Ypsomed Group operates an international network of production sites, distributors and subsidiaries. The company employs around 1,350 people. Ypsomed markets its innovative diabetes care product in more than 50 countries under the mylife Diabetescare brand. The Ypsomed Holding share price (YPSN) is set and traded on the SIX Swiss Exchange.